Akeso (HKG:9926) swung to an attributable loss of 514.5 million yuan in 2024 from a profit of 2.03 billion yuan in 2023, according to a Sunday filing with the Hong Kong bourse.
The biopharmaceuticals producer swung to a loss per share of 0.60 yuan from earnings per share of 2.42 yuan in the previous year.
Revenue declined 53% to 2.12 billion yuan from 4.53 billion yuan a year earlier.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。